Rohto Pharmaceutical Co (TSE:4527) Total Liabilities : 円96,150 Mil (As of Dec. 2023)

View and export this data going back to 1962. Start your Free Trial

What is Rohto Pharmaceutical Co Total Liabilities?

Rohto Pharmaceutical Co's Total Liabilities for the quarter that ended in Dec. 2023 was 円96,150 Mil.

Rohto Pharmaceutical Co's quarterly Total Liabilities increased from Jun. 2023 (円92,872.00 Mil) to Sep. 2023 (円96,159.00 Mil) but then declined from Sep. 2023 (円96,159.00 Mil) to Dec. 2023 (円96,150.00 Mil).

Rohto Pharmaceutical Co's annual Total Liabilities increased from Mar. 2022 (円90,884.00 Mil) to Mar. 2023 (円94,601.00 Mil) and increased from Mar. 2023 (円94,601.00 Mil) to Mar. 2024 (円99,142.00 Mil).

Rohto Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Rohto Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rohto Pharmaceutical Co Total Liabilities Chart

Rohto Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

75,614.00

69,538.00

90,884.00

94,601.00

99,142.00

Rohto Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															94,601.00	92,872.00	96,159.00	96,150.00	99,142.00

Rohto Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Rohto Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	87087	+	(5190	+	4317
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	2548)
	=	99,142

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	346175	-	247033
	=	99,142

Rohto Pharmaceutical Co's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	83633	+	(5273	+	3988
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	3256)
	=	96,150

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	342160	-	246010
	=	96,150

Rohto Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Rohto Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Rohto Pharmaceutical Co (TSE:4527) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Rohto Pharmaceutical Co Ltd (TSE:4527) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

4527:Mexico

Address

1-8-1, Tatsumi-nishi, Ikuno-ku, Osaka, JPN, 544-8666

Website

https://www.rohto.co.jp

Rohto Pharmaceutical Co Ltd is a Japan-based manufacturer and marketer of pharmaceutical products, cosmetics, and functional foods. It undertakes manufacture and sales activities mainly in the health and beauty care categories. The company comprises the four geographical reportable segments of Japan, America, Europe, and Asia. In each segment, it manufactures and sales eye care products including eye drops and eyewash preparations, skincare products including dermal medicines, lip balm, sunscreens, and functional cosmetics, among others, internal medicines and food products including gastrointestinal medicines, traditional Chinese herbal medicines and supplements, and other products and services, such as in-vitro test kits.

Rohto Pharmaceutical Co (TSE:4527) Headlines

No Headlines